Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + R-CHOP
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Celecoxib + R-CHOP is a combination chemoimmunotherapy regimen being evaluated for the treatment of newly diagnosed, advanced CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL). The regimen integrates celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, with the standard R-CHOP backbone consisting of rituximab (a CD20-directed monoclonal antibody), cyclophosphamide, doxorubicin, vincristine, and prednisone. The addition of celecoxib is intended to target the inflammatory microenvironment and COX-2 expression, which are linked to poor outcomes and immune evasion in aggressive B-cell lymphomas. This specific investigation is led by Sun Yat-sen University in a multicenter Phase II clinical trial.
- Other names
- Celecoxib plus R-CHOPCelecoxib-R-CHOP
02
Targets
TOP2A (DNA topoisomerase II)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DNACD20 (B-lymphocyte antigen CD20)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on celecoxib + R-CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + R-CHOP.